Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine

Kay, 2001, Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics, Nat Med, 7, 33, 10.1038/83324 Crystal, 2014, Adenovirus: the first effective in vivo gene delivery vector, Hum Gene Ther, 25, 3, 10.1089/hum.2013.2527 Breyer, 2001, Adenoviral vector-mediated gene transfer for human gene therapy, Curr Gene Ther, 1, 149, 10.2174/1566523013348689 Seymour, 2011, Adenovirus: teaching an old dog new tricks, Hum Gene Ther, 22, 1041, 10.1089/hum.2011.2517 Rauschhuber, 2012, New insights into stability of recombinant adenovirus vector genomes in mammalian cells, Eur J Cell Biol, 91, 2, 10.1016/j.ejcb.2011.01.006 Jin, 2014, Current progress in gene delivery technology based on chemical methods and nano-carriers, Theranostics, 4, 240, 10.7150/thno.6914 Wang, 2013, Non-viral gene delivery methods, Curr Pharm Biotechnol, 14, 46 Manjila, 2013, Novel gene delivery systems, Int J Pharm Investig, 3, 1, 10.4103/2230-973X.108958 Nayerossadat, 2012, Viral and nonviral delivery systems for gene delivery, Adv Biomed Res, 1, 27, 10.4103/2277-9175.98152 Katare, 2010, Progress in gene therapy: a review, Int J Toxicol Pharm Res, 1, 33 Gardlík, 2005, Vectors and delivery systems in gene therapy, Med Sci Monit, 11, RA110 Robertson, 1996, Epstein-Barr virus vectors for gene delivery to B lymphocytes, Proc Natl Acad Sci U S A, 93, 11334, 10.1073/pnas.93.21.11334 Hirai, 1997, Use of EBV-based Vector/HVJ-liposome complex vector for targeted gene therapy of EBV-associated neoplasms, Biochem Biophys Res Commun, 241, 112, 10.1006/bbrc.1997.7776 Ohe, 1995, Construction of a novel bovine papillomavirus vector without detectable transforming activity suitable for gene transfer, Hum Gene Ther, 6, 325, 10.1089/hum.1995.6.3-325 Verma, 1997, Gene therapy – promises, problems and prospects, Nature, 389, 239, 10.1038/38410 Mountain, 2000, Gene therapy: the first decade, Trends Biotechnol, 18, 119, 10.1016/S0167-7799(99)01416-X Luo, 2000, Synthetic DNA delivery systems, Nat Biotechnol, 18, 33, 10.1038/71889 Doerfler, 1997, Integration of foreign DNA and its consequences in mammalian systems, Trends Biotechnol, 15, 297, 10.1016/S0167-7799(97)01061-5 Garrick, 1998, Repeat-induced gene silencing in mammals, Nat Genet, 18, 56, 10.1038/ng0198-56 Remus, 1999, Insertion of foreign DNA into an established mammalian genome can alter the methylation of cellular DNA sequences, J Virol, 73, 1010, 10.1128/JVI.73.2.1010-1022.1999 Ehrhardt, 2008, Episomal vectors for gene therapy, Curr Gene Ther, 8, 147, 10.2174/156652308784746440 Van Craenenbroeck, 2000, Episomal vectors for gene expression in mammalian cells, Eur J Biochem, 267, 5665, 10.1046/j.1432-1327.2000.01645.x Belt, 1991, Efficient cDNA cloning by direct phenotypic correction of a mutant human cell line (HPRT-) using an Epstein-Barr virus-derived cDNA expression vector, Nucleic Acids Res, 19, 4861, 10.1093/nar/19.18.4861 Mazda, 1997, Extremely efficient gene transfection into lympho-hematopoietic cell lines by Epstein-Barr virus-based vectors, Methods, 204, 143 Friedrich, 2018, Distinct patterns of MCM protein binding in nuclei of S phase and rereplicating SV40-infected monkey kidney cells, Cytom Part Soc Anal Cytol, 68, 10 Valls, 2003, The SV40 T antigen modulates CBP histone acetyltransferase activity, Nucleic Acids Res, 31, 3114, 10.1093/nar/gkg418 Darimont, 2003, Reconstitution of telomerase activity combined with HPV-E7 expression allow human preadipocytes to preserve their differentiation capacity after immortalization, Cell Death Differ, 10, 1025, 10.1038/sj.cdd.4401273 Harris, 1996, BK virus large T antigen: interactions with the retinoblastoma family of tumor suppressor proteins and effects on cellular growth control, J Viol, 70, 2378 Liu, 2007, Applications of Sleeping Beauty transposons for nonviral gene therapy, IUBMB Life, 59, 374, 10.1080/15216540701435722 Ehrhardt, 2005, A direct comparison of two nonviral gene therapy vectors for somatic integration: in vivo evaluation of the bacteriophage integrase phiC31 and the Sleeping Beauty transposase, Mol Ther, 11, 695, 10.1016/j.ymthe.2005.01.010 Muñoz-López, 2010, DNA transposons: nature and applications in genomics, Curr Genomics, 11, 115, 10.2174/138920210790886871 Hackett, 2011, Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies, Curr Gene Ther, 11, 341, 10.2174/156652311797415827 Skipper, 2013, DNA transposon-based gene vehicles-scenes from an evolutionary drive, J Biomed Sci, 20, 10.1186/1423-0127-20-92 Ivics, 2015, Sleeping beauty transposition, Microbiol Spectr, 3, 10.1128/microbiolspec.MDNA3-0042-2014 Wang, 2014, State-of-the-art human gene therapy: part I, Gene Deliv Technol Discov Med, 18, 67 Grabundzija, 2010, Comparative analysis of transposable element vector systems in human cells, Mol Ther, 18, 1200, 10.1038/mt.2010.47 Plasterk, 1993, Molecular mechanisms of transposition and its control, Cell, 74, 781, 10.1016/0092-8674(93)90458-3 Ivics, 2006, Transposons for gene therapy!, Curr Gene Ther, 6, 593, 10.2174/156652306778520647 Chen, 2015, Sustained high level transgene expression in mammalian cells mediated by the optimized piggyBac transposon system, Genes Dis, 2, 96, 10.1016/j.gendis.2014.12.001 Yant, 2004, Mutational analysis of the N-terminal DNA-binding domain of sleeping beauty transposase: critical residues for DNA binding and hyperactivity in mammalian cells, Mol Cell Biol, 24, 9239, 10.1128/MCB.24.20.9239-9247.2004 Sakuma, 2012, Lentiviral vectors: basic to translational, Biochem J, 443, 603, 10.1042/BJ20120146 Ertl, 2012, Progress in the development of hepatitis C virus vaccines, Mol Ther, 20, 697, 10.1038/mt.2012.30 Lachmann, 1997, The use of herpes simplex virus-based vectors for gene delivery to the nervous system, Mol Med Today, 3, 404, 10.1016/S1357-4310(97)01106-4 Federici, 2009, Comparative analysis of HIV-1-based lentiviral vectors bearing lyssavirus glycoproteins for neuronal gene transfer, Genet Vaccines Ther, 7, 1, 10.1186/1479-0556-7-1 Hacein-Bey-Abina, 2010, Efficacy of gene therapy for X-linked severe combined immunodeficiency, N Engl J Med, 363, 355, 10.1056/NEJMoa1000164 Anson, 2004, The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery, Genet Vaccines Ther, 2, 10.1186/1479-0556-2-9 Laufs, 2002, Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells, Blood, 101, 2191, 10.1182/blood-2002-02-0627 Hacein-Bey-Abina, 2003, LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1, Science, 302, 415, 10.1126/science.1088547 Hacein-Bey-Abina, 2002, Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy, N Engl J Med, 346, 1185, 10.1056/NEJMoa012616 Fischer, 2005, Gene therapy of severe combined immunodeficiency disease: proof of principle of efficiency and safety issues. Gene therapy primary immunodeficiencies retrovirus lentivirus genome, Bull Acad Natl Med, 189, 779 Fox, 2003, US authorities uphold suspension of SCID gene therapy, Nat Biotechnol, 21, 217, 10.1038/nbt0303-217 Buckley, 2002, Gene therapy for SCID-a complication after remarkable progress, Lancet, 360, 1185, 10.1016/S0140-6736(02)11290-6 Wu, 2004, Integration target site selection for retroviruses and transposable elements, Cell Mol Life, 19 Cereseto, 2004, Integration site selection by retroviruses, AIDS Rev, 6, 13 Engelman, 2003, The roles of cellular factors in retroviral integration, Curr Top Microbiol Immunol, 281, 209 Cockrell, 2007, Gene delivery by lentivirus vectors, Mol Biotechnol, 36, 184, 10.1007/s12033-007-0010-8 Kafri, 2004, Gene delivery by lentivirus vectors an overview, Methods Mol Biol, 246, 367 Balaggan, 2011, Ocular gene delivery using lentiviral vectors, Gene Ther, 19, 145, 10.1038/gt.2011.153 Wong, 2006, Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications, Hum Gene Ther, 17, 1, 10.1089/hum.2006.17.1 Azzouz, 2002, J Neurosci, 22, 10302, 10.1523/JNEUROSCI.22-23-10302.2002 Betchen, 2003, Future and current surgical therapies in Parkinson's disease, Curr Opin Neurol, 16, 487, 10.1097/01.wco.0000084227.82329.ae Vannucci, 2013, Viral vectors: a look back and ahead on gene transfer technology, New Microbiol, 36, 1 Dropulić, 2011, Lentiviral vectors: their molecular design, safety, and use in laboratory and preclinical research, Hum Gene Ther, 22, 649, 10.1089/hum.2011.058 Howarth, 2010, Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells), Cell Biol Toxicol, 26, 1, 10.1007/s10565-009-9139-5 Mátrai, 2010, Recent advances in lentiviral vector development and applications, Mol Ther, 18, 477, 10.1038/mt.2009.319 Samulski, 2014, AAV-mediated gene therapy for research and therapeutic purposes, Annu Rev Virol, 1, 427, 10.1146/annurev-virology-031413-085355 Balakrishnan, 2014, Basic biology of adeno-associated virus (AAV) vectors used in gene therapy, Curr Gene Ther, 14, 86, 10.2174/1566523214666140302193709 Waehler, 2007, Engineering targeted viral vectors for gene therapy, Nat Rev Genet, 8, 573, 10.1038/nrg2141 Nayak, 2009, Progress and prospects: immune responses to viral vectors, Gene Ther, 17, 295, 10.1038/gt.2009.148 McCarty, 2001, Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis, Gene Ther, 8, 1248, 10.1038/sj.gt.3301514 Walther, 2000, Viral vectors for gene transfer: a review of their use in the treatment of human diseases, Drugs, 60, 249, 10.2165/00003495-200060020-00002 Teramato, 2000, Crisis of adenoviruses in human gene therapy, Lancet, 355, 1911, 10.1016/S0140-6736(05)73358-4 Giacca, 2012, Virus-mediated gene delivery for human gene therapy, J Control Release, 161, 377, 10.1016/j.jconrel.2012.04.008 Smith, 2008, Adeno-associated virus integration: virus versus vector, Gene Ther, 15, 817, 10.1038/gt.2008.55 Flotte, 2013, Birth of a new therapeutic platform: 47 years of adeno-associated virus biology from virus discovery to licensed gene therapy, Mol Ther, 21, 1976, 10.1038/mt.2013.226 Lai, 2002, Adenovirus and adeno-associated virus vectors, DNA Cell Biol, 21, 895, 10.1089/104454902762053855 Flotte, 1996, A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease, Hum Gene Ther, 7, 1145, 10.1089/hum.1996.7.9-1145 Kay, 2000, Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector, Nat Genet, 24, 257, 10.1038/73464 Duque, 2009, Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons, Mol Ther, 17, 1187, 10.1038/mt.2009.71 Foust, 2009, Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes, Nat Biotechnol, 27, 59, 10.1038/nbt.1515 Yang, 2014, Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10, Mol Ther, 22, 1299, 10.1038/mt.2014.68 Zhang, 2011, Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system, Mol Ther, 19, 1440, 10.1038/mt.2011.98 Nagabhushan Kalburgi, 2013, Recent gene therapy advancements for neurological diseases, Discov Med, 15, 111 Lachmann, 2004, J. Herpes simplex virus-based vectors, Int Pathol, 85, 177, 10.1111/j.0959-9673.2004.00383.x Hukkanen, 2010, Herpesvirus vectors in gene therapy, Open Virol J, 4, 94 Liu, 2007, A novel human foamy virus mediated gene transfer of GAD67 reduces neuropathic pain following spinal cord injury, Neurosci Lett, 432, 13, 10.1016/j.neulet.2007.11.054 Burton, 2002, Gene delivery using herpes simplex virus vectors, DNA Cell Biol, 21, 915, 10.1089/104454902762053864 Lentz, 2011, Viral vectors for gene delivery to the central nervous system, Neurobiol Dis, 48, 179, 10.1016/j.nbd.2011.09.014 de Silva, 2009, Herpes virus amplicon vectors, Viruses, 1, 594, 10.3390/v1030594 Marconi, 2009, HSV as a vector in vaccine development and gene therapy, Adv Exp Med Biol, 655, 118, 10.1007/978-1-4419-1132-2_10 Marconi, 2010, HSV-1-derived helper-independent defective vectors, replicating vectors and amplicon vectors, for the treatment of brain diseases, Curr Opin Drug Discov Devel, 13, 169 Manservigi, 2010, HSV recombinant vectors for gene therapy, Open Virol J, 4, 123 Goss, 2014, Herpes simplex virus-based nerve targeting gene therapy in pain management, J Pain Res, 7, 71 Agarwalla, 2012, Oncolytic herpes simplex virus engineering and preparation, Methods Mol Biol, 797, 1, 10.1007/978-1-61779-340-0_1 Berto, 2005, Development and application of replication-incompetent HSV-1-based vectors, Gene Ther, 1, S98, 10.1038/sj.gt.3302623 Burton, 2001, Multiple applications for replication-defective herpes simplex virus vectors, Stem Cells, 19, 358, 10.1634/stemcells.19-5-358 Goins, 2009, Herpes simplex virus vector-mediated gene delivery for the treatment of lower urinary tract pain, Gene Ther, 16, 558, 10.1038/gt.2009.19 Wolfe, 2009, A human trial of HSV-mediated gene transfer for the treatment of chronic pain, Gene Ther, 16, 455, 10.1038/gt.2009.17 Goss, 2002, Herpes vector-mediated expression of proenkephalin reduces bone cancer pain, Ann Neurol, 52, 662, 10.1002/ana.10343 Pulkkanen, 2005, Gene therapy for malignant glioma: current clinical status, Mol Ther, 12, 585, 10.1016/j.ymthe.2005.07.357 Wong, 2012, Targeted oncolytic herpes simplex viruses for aggressive cancers, Curr Pharm Biotechnol, 13, 1786, 10.2174/138920112800958751 Davison, 2003, Genetic content and evolution of adenoviruses, J Gen Virol, 84, 2895, 10.1099/vir.0.19497-0 Lasaro, 2009, New insights on adenovirus as vaccine vectors, Mol Ther, 17, 1333, 10.1038/mt.2009.130 Lehrman, 1999, Virus treatment questioned after gene therapy death, Nature, 401, 517, 10.1038/43977 Bett, 1993, Packaging capacity and stability of human adenovirus type 5 vectors, J Virol, 67, 5911, 10.1128/jvi.67.10.5911-5921.1993 Reid, 2002, Intravascular adenoviral agents in cancer patients: lessons from clinical trials, Cancer Gene Ther, 9, 979, 10.1038/sj.cgt.7700539 Raper, 2003, Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer, Mol Genet Metab, 80, 148, 10.1016/j.ymgme.2003.08.016 Marshall, 1999, Gene therapy death prompts review of adenovirus vector, Science, 286, 2244, 10.1126/science.286.5448.2244 Choi, 2013, Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers, Cancer Gene Ther, 20, 70, 10.1038/cgt.2012.95 Russell, 2012, Oncolytic virotherapy, Nat Biotechnol, 30, 658, 10.1038/nbt.2287 Cerullo, 2010, Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients, Cancer Res, 70, 4297, 10.1158/0008-5472.CAN-09-3567 Kaufmann, 2012, Virus chimeras for gene therapy, vaccination, and oncolysis: adenoviruses and beyond, Trends Mol Med, 18, 365, 10.1016/j.molmed.2012.04.008 Ramos-Kuri, 2015, Dominant negative Ras attenuates pathological ventricular remodeling in pressure overload cardiac hypertrophy, Biochim Biophys Acta, 1853, 2870, 10.1016/j.bbamcr.2015.08.006 Vorburger, 2002, Adenoviral gene therapy, Oncologist, 7, 46, 10.1634/theoncologist.7-1-46 Parks, 1996, A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal, Proc Natl Acad Sci U S A, 93, 13565, 10.1073/pnas.93.24.13565 Sandig, 2000, Optimization of the helper-dependent adenovirus system for production and potency in vivo, Proc Natl Acad Sci U S A, 97, 1002, 10.1073/pnas.97.3.1002 Reddy, 2002, Sustained human factor in hemophilia following systemic delivery of a gutless adenoviral vector, Mol Ther, 5, 63, 10.1006/mthe.2001.0510 Ng, 2001, Development of a FLP/frt system for generating helper-dependent adenoviral vectors, Mol Ther, 3, 809, 10.1006/mthe.2001.0323 Medico, 2001, A gene trap vector system for identifying transcriptionally responsive genes, Nat Biotechnol, 19, 579, 10.1038/89343 Kalburgi, 2013, Nagabhushan Recent gene therapy advancements for neurological diseases, Discov Med, 15, 111 He, 2004, Adenoviral vectors, Curr Protoc Hum Genet, 12.4.1 He, 1998, A simplified system for generating recombinant adenoviruses, Proc Natl Acad Sci U S A, 95, 2509, 10.1073/pnas.95.5.2509 Mizuguchi, 2001, Approaches for generating recombinant adenovirus vectors, Adv Drug Deliv Rev, 52, 165, 10.1016/S0169-409X(01)00215-0 Danthinne, 2000, Production of first generation adenovirus vectors: a review, Gene Ther, 7, 1707, 10.1038/sj.gt.3301301 Luo, 2007, A protocol for rapid generation of recombinant adenoviruses using the AdEasy system, Nat Protoc, 2, 1236, 10.1038/nprot.2007.135 Berkner, 1983, Generation of adenovirus by transfection of plasmids, Nucleic Acids Res, 11, 6003, 10.1093/nar/11.17.6003 Mizuguchi, 1998, Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method, Hum Gene Ther, 9, 2577, 10.1089/hum.1998.9.17-2577 Hardy, 1997, Construction of adenovirus vectors through Cre-lox recombination, J Virol, 71, 1842, 10.1128/jvi.71.3.1842-1849.1997 Ng, 2002, Cre levels limit packaging signal excision efficiency in the Cre/lox Adenoviral vector system, J Virol, 76, 4181, 10.1128/JVI.76.9.4181-4189.2002 Ketner, 1994, Efficient manipulation of the human adenovirus genome as an infectious yeast artificial chromosome clone, Proc Natl Acad Sci U S A, 91, 6186, 10.1073/pnas.91.13.6186 Chartier, 1996, Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli, J Virol, 70, 4805, 10.1128/jvi.70.7.4805-4810.1996 Crouzet, 1997, Recombinational construction in Escherichia coli of infectious adenoviral genomes, Proc Natl Acad Sci U S A, 94, 1414, 10.1073/pnas.94.4.1414 Umana, 2001, Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination, Nat Biotechnol, 19, 582, 10.1038/89349 Zhao, 2014, Adenovirus-mediated gene transfer in mesenchymal stem cells can be significantly enhanced by the cationic polymer polybrene, PLoS One, 9, e92908, 10.1371/journal.pone.0092908 Wu, 2014, Overexpression of Ad5 precursor terminal protein accelerates recombinant adenovirus packaging and amplification in HEK-293 packaging cells, Gene Ther, 21, 629, 10.1038/gt.2014.40 Wei, 2017, Engineering the rapid adenovirus production and amplification (RAPA) cell line to expedite the generation of recombinant adenoviruses, Cell Physiol Biochem, 41, 2383, 10.1159/000475909 Jaffe, 1992, Adenovirus-mediated in vivo gene transfer and expression in normal rat liver, Nat Genet, 1, 372, 10.1038/ng0892-372 Rosenfeld, 1992, In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium, Cell, 68, 143, 10.1016/0092-8674(92)90213-V Yang, 1994, Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy, Proc Natl Acad Sci U S A, 91, 4407, 10.1073/pnas.91.10.4407 Yang, 1996, Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo, Gene Ther, 3, 137 Kotterman, 2015, Viral vectors for gene therapy: translational and clinical outlook, Annu Rev Biomed Eng, 17, 63, 10.1146/annurev-bioeng-071813-104938 Ginn, 2013, Gene therapy clinical trials worldwide to -an update, J Gene Med, 15, 65, 10.1002/jgm.2698 Wu, 2005, Adenovirus-mediated transgene-engineered dendritic cell vaccine of cancer, Curr Gene Ther, 5, 237, 10.2174/1566523053544272 Tagawa, 2008, Cancer therapy with local oncolysis and topical cytokine secretion, Front Biosci Libr, 13, 2578, 10.2741/2867 Matthews, 2009, Advancements in adenoviral based virotherapy for ovarian cancer, Adv Drug Deliv Rev, 61, 836, 10.1016/j.addr.2009.04.012 Fukazawa, 2010, Adenovirus-mediated cancer gene therapy and virotherapy (Review), Int J Mol Med, 25, 3 Aguilar, 2011, Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development, J Cell Biochem, 112, 1969, 10.1002/jcb.23126 Aurisicchio, 2012, Genetic cancer vaccines: current status and perspectives, Expert Opin Biol Ther, 12, 1043, 10.1517/14712598.2012.689279 Duarte, 2012, Suicide gene therapy in cancer: where do we stand now?, Cancer Lett, 324, 160, 10.1016/j.canlet.2012.05.023 Deisseroth, 2012, TAA/ecdCD40L adenoviral prime-protein boost vaccine for cancer and infectious diseases, Cancer Gene Ther, 20, 65, 10.1038/cgt.2012.87 Wold, 2013, Adenovirus vectors for gene therapy, vaccination and cancer gene therapy, Curr Gene Ther, 13, 421, 10.2174/1566523213666131125095046 Peng, 2005, Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers, Hum Gene Ther, 16, 1016, 10.1089/hum.2005.16.1016 Wold, 2013, Adenoviruses, vol. 1, 1345 Nemunaitis, 2011, Head and neck cancer: response to p53-based therapeutics, Head Neck, 33, 131, 10.1002/hed.21364 Roth, 2006, Adenovirus p53 gene therapy, Expert Opin Biol Ther, 6, 55, 10.1517/14712598.6.1.55 Senzer, 2009, A review of contusugene ladenovec (Advexin) p53 therapy, Curr Opin Mol Ther, 11, 54 Nemunaitis, 2009, Biomarkers predict p53 gene therapy efficacy in recurrent squamous cell carcinoma of the head and neck, Clin Cancer Res, 15, 7719, 10.1158/1078-0432.CCR-09-1044 Tian, 2009, Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial, Anticancer Drugs, 20, 389, 10.1097/CAD.0b013e32832a2df9 Ma, 2009, Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China, Drug Des Devel Ther, 2, 115 Shi, 2009, An update on gene therapy in China, Curr Opin Mol Ther, 11, 547 Shirakawa, 2008, The current status of adenovirus-based cancer gene therapy, Mol Cells, 25, 462 Li, 2015, Key points of basic theories and clinical practice in rAd-p53 ( Gendicine ™) gene therapy for solid malignant tumors, Expert Opin Biol Ther, 15, 437, 10.1517/14712598.2015.990882 Vaillancourt, 2005, Inefficient killing of quiescent human epithelial cells by replicating adenoviruses: potential implications for their use as oncolytic agents, Cancer Gene Ther, 12, 691, 10.1038/sj.cgt.7700840 Ferrari, 2008, Epigenetic reprogramming by adenovirus e1a, Science, 321, 1086, 10.1126/science.1155546 Vähä-Koskela, 2007, Oncolytic viruses in cancer therapy, Cancer Lett, 254, 178, 10.1016/j.canlet.2007.02.002 Ganly, 2000, A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer, Clin Cancer Res, 6, 798 Kim, 2002, Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy, Cancer Gene Ther, 9, 725, 10.1038/sj.cgt.7700494 Nemunaitis, 2000, Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an EkD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial, Cancer Res, 60, 1B Liu, 2007, Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress, Nat Clin Pract Oncol, 4, 101, 10.1038/ncponc0736 Khuri, 2000, A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer, Nat Med, 6, 879, 10.1038/78638 Yu, 2007, Clinical trials with oncolytic adenovirus in China, Curr Cancer Drug Targets, 7, 141, 10.2174/156800907780058817 Chira, 2015, Progresses towards safe and efficient gene therapy vectors, Oncotarget, 6, 30675, 10.18632/oncotarget.5169 DeWeese, 2001, A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy, Cancer Res, 61, 7464 Small, 2006, A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer, Mol Ther, 14, 107, 10.1016/j.ymthe.2006.02.011 Fukuda, 2008, E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer, Cancer Gene Ther, 16, 126, 10.1038/cgt.2008.67 Li, 2005, Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer, Cancer Res, 65, 1941, 10.1158/0008-5472.CAN-04-3666 Kim, 2003, Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner, Hum Gene Ther, 14, 1415, 10.1089/104303403769211637 Rodriguez, 1997, Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells, Cancer Res, 57, 2559 Nettelbeck, 2002, Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter, Cancer Res, 62, 4663 Conrad, 2005, Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization, Cancer Gene Ther, 12, 284, 10.1038/sj.cgt.7700750 Smaill, 2013, A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity, Sci Transl Med, 5, 205ra134, 10.1126/scitranslmed.3006843 McElrath, 2008, HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis, Lancet, 372, 1894, 10.1016/S0140-6736(08)61592-5 Harro, 2009, Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults, Clin Vaccine, 16, 1285, 10.1128/CVI.00144-09 Buchbinder, 2008, Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial, Lancet, 372, 1881, 10.1016/S0140-6736(08)61591-3 Mennechet, 2015, Ebola virus vaccine: benefit and risks of adenovirus-based vectors, Expert Rev Vaccines, 14, 1471, 10.1586/14760584.2015.1083429 De Santis, 2016, Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study, Lancet Infect Dis, 16, 311, 10.1016/S1473-3099(15)00486-7 Green, 2015, Chimpanzee adenovirus-and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults, Sci Transl Med, 7, 300ra126, 10.1126/scitranslmed.aac5745 Milligan, 2016, Safety and immunogenicity of novel adenovirus type 26-and modified vaccinia ankara-vectored Ebola vaccines: clinical trial, JAMA, 315, 1610, 10.1001/jama.2016.4218 Zhou, 2015, Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine, Curr Opin Immunol, 35, 131, 10.1016/j.coi.2015.06.006 Zhu, 2015, Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial, Lancet, 385, 2272, 10.1016/S0140-6736(15)60553-0 Hill, 2010, Prime-boost vectored malaria vaccines: progress and prospects, Hum Vaccin, 6, 78, 10.4161/hv.6.1.10116 Scallan, 2013, An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models, Clin Vaccine, 20, 85, 10.1128/CVI.00552-12 Peters, 2013, Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-γ T cell responses in humans, Vaccine, 31, 1752, 10.1016/j.vaccine.2013.01.023 Alexander, 2012, Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin, Plos One, 7, e31177, 10.1371/journal.pone.0031177 Chiuppesi, 2012, A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections, J Virol, 86, 6563, 10.1128/JVI.00302-12 Wei, 2010, Induction of broadly neutralizing H1N1 influenza antibodies by vaccination, Science, 329, 1060, 10.1126/science.1192517 Gray, 2010, Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine, Curr Opin HIV AIDS, 5, 357, 10.1097/COH.0b013e32833d2d2b Liu, 2009, Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys, Nature, 457, 87, 10.1038/nature07469 Hammer, 2013, Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine, N Engl J Med, 369, 2083, 10.1056/NEJMoa1310566 Walsh, 2016, Vaccination with 1 envelope sequences and heterologous adenovirus vectors cell responses to conserved regions: HVTN 083, J Infect Dis, 213, 541, 10.1093/infdis/jiv496 Baden, 2016, Assessment of the safety and immunogenicity of 2 novel vaccine platforms for HIV-1 prevention: trial, Ann Intern Med, 164, 313, 10.7326/M15-0880 Ewer, 2016, Chimpanzee adenovirus Ebola vaccine boosted with MVA, N Engl J Med, 374, 1635, 10.1056/NEJMoa1411627 Stanley, 2014, Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge, Nat Med, 20, 1126, 10.1038/nm.3702 Deen, 2015, Ebola in semen of Ebola virus disease survivors-preliminary report, N Engl J Med, 1 Varkey, 2015, Persistence of Ebola virus in ocular fluid during convalescence, N Engl J Med, 372, 2423, 10.1056/NEJMoa1500306 Martínez, 2015, Ebola virus infection: overview and update on prevention and treatment, Infect Dis Ther, 4, 365, 10.1007/s40121-015-0079-5 Biswas, 2014, Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure, Plos One, 9, e107903, 10.1371/journal.pone.0107903 Mast, 2009, International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials, Vaccine, 28, 950, 10.1016/j.vaccine.2009.10.145 Abbink, 2007, Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D, J Virol, 81, 4654, 10.1128/JVI.02696-06 Swenson, 2008, Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections, Clin Vaccine, 15, 460, 10.1128/CVI.00431-07 Pratt, 2010, Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector, Clin Vaccine, 17, 572, 10.1128/CVI.00467-09 Ledgerwood, 2010, A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults, Vaccine, 29, 304, 10.1016/j.vaccine.2010.10.037 Luo, 2005, Gene therapy for bone regeneration, Curr Gene Ther, 5, 167, 10.2174/1566523053544218 Luther, 2011, BMP-9 induced osteogenic differentiation of mesenchymal stem cells: molecular mechanism and therapeutic potential, Curr Gene Ther, 11, 229, 10.2174/156652311795684777 Lamplot, 2013, BMP9 signaling in stem cell differentiation and osteogenesis, Am J Stem Cells, 2, 1 Shenaq, 2010, Mesenchymal progenitor cells and their orthopedic applications: forging a path towards clinical trials, Stem Cells Int, 2010, 519028, 10.4061/2010/519028 Rastegar, 2010, Mesenchymal stem cells: molecular characteristics and clinical applications, World J Stem Cells, 2, 67, 10.4252/wjsc.v2.i4.67 Thomas, 2003, Progress and problems with the use of viral vectors for gene therapy, Nat Rev Genet, 4, 346, 10.1038/nrg1066 Luu, 2007, Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells, J Orthop Res, 25, 665, 10.1002/jor.20359 Deng, 2008, Regulation of osteogenic differentiation during skeletal development, Front Biosci, 13, 2001, 10.2741/2819 Chen, 2010, Insulin-like growth factor 2 (IGF-2) potentiates BMP-9-induced osteogenic differentiation and bone formation, J Bone Min Res, 25, 2447, 10.1002/jbmr.133 Liu, 2013, Cross-talk between EGF and BMP9 signalling pathways regulates the osteogenic differentiation of mesenchymal stem cells, J Cell Mol Med, 17, 1160, 10.1111/jcmm.12097 Zhang, 2015, Canonical Wnt signaling acts synergistically on BMP9-induced osteo/odontoblastic differentiation of stem cells of dental apical papilla (SCAPs), Biomaterials, 39, 145, 10.1016/j.biomaterials.2014.11.007 Zhang, 2010, Retinoic acids potentiate BMP9-induced osteogenic differentiation of mesenchymal progenitor cells, PLoS One, 5, e11917, 10.1371/journal.pone.0011917 Liao, 2017, Notch signaling augments BMP9-induced Bone formation by promoting the osteogenesis-angiogenesis coupling process in mesenchymal stem cells (MSCs), Cell Physiol Biochem, 41, 1905, 10.1159/000471945 Wang, 2017, Nel-Like Molecule-1 (Nell1) is regulated by bone morphogenetic protein 9 (BMP9) and potentiates BMP9-induced osteogenic differentiation at the expense of adipogenesis in mesenchymal stem cells, Cell Physiol Biochem, 41, 484, 10.1159/000456885 Reddi, 2001, Bone morphogenetic proteins: from basic science to clinical applications, J Bone Jt Surg Am, 83-A, S1, 10.2106/00004623-200100001-00001 Cheng, 2003, Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs), J Bone Jt Surg Am, 85-A, 1544, 10.2106/00004623-200308000-00017 Kang, 2009, A comprehensive analysis of the dual roles of BMPs in regulating adipogenic and osteogenic differentiation of mesenchymal progenitor cells, Stem Cells Dev, 18, 545, 10.1089/scd.2008.0130 Kang, 2004, Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery, Gene Ther, 11, 1312, 10.1038/sj.gt.3302298 Sakou, 1998, Bone morphogenetic proteins: from basic studies to clinical approaches, Bone, 22, 591, 10.1016/S8756-3282(98)00053-2 Einhorn, 2001, Bone regeneration: new findings and potential clinical applications, J Am Acad Orthop Surg, 9, 157, 10.5435/00124635-200105000-00002 Barnes, 1999, Growth factor regulation of fracture repair, J Bone Min Res, 14, 1805, 10.1359/jbmr.1999.14.11.1805 Lieberman, 1999, The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats, J Bone Jt Surg Am, 81, 905, 10.2106/00004623-199907000-00002 Park, 2003, Bone regeneration in critical size defects by cell-mediated BMP-2 gene transfer: a comparison of adenoviral vectors and liposomes, Gene Ther, 10, 1089, 10.1038/sj.gt.3301960 Govender, 2002, Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients, J Bone Jt Surg Am, 84-A, 2123, 10.2106/00004623-200212000-00001 Boden, 2002, Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies, Spine (Phila Pa 1976), 27, 2662, 10.1097/00007632-200212010-00005 Friedlaender, 2001, Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions, J Bone Jt Surg Am, 83-A, S151 Johnsson, 2002, Randomized radiostereometric study comparing osteogenic protein-1 (BMP-7) and autograft bone in human noninstrumented posterolateral lumbar fusion: 2002 Volvo Award in clinical studies, Spine (Phila Pa 1976), 27, 2654, 10.1097/00007632-200212010-00004 Dayoub, 2003, Human mesenchymal stem cells transduced with recombinant bone morphogenetic protein-9 adenovirus promote osteogenesis in rodents, Tissue Eng, 9, 347, 10.1089/107632703764664819 Varady, 2001, Morphologic analysis of BMP-9 gene therapy-induced osteogenesis, Hum Gene Ther, 12, 697, 10.1089/104303401300057423 Paul, 2003, Potential use of Sox9 gene therapy for intervertebral degenerative disc disease, Spine (Phila Pa 1976), 28, 755, 10.1097/01.BRS.0000058946.64222.92 Mehta, 2005, Characterization of adenovirus-mediated gene transfer in rabbit flexor tendons, J Hand Surg Am, 30, 136, 10.1016/j.jhsa.2004.08.010 Bolt, 2007, BMP-14 gene therapy increases tendon tensile strength in a rat model of Achilles tendon injury, J Bone Jt Surg Am, 89, 1315, 10.2106/00004623-200706000-00021 Xiong, 2006, Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses, J Virol, 80, 27, 10.1128/JVI.80.1.27-37.2006 Xiong, 2008, Immunization against the transgene but not the TetReduces expression from gutless adenoviral vectors in the brain, Mol Ther, 16, 343, 10.1038/sj.mt.6300375 Shi, 2006, A convenient plasmid system for construction of helper-dependent adenoviral vectors and its application for analysis of the breast-cancer-specific mammaglobin promoter, J Gene Med, 8, 442, 10.1002/jgm.867 Gonzalez-Aparicio, 2011, Self-inactivating helper virus for the production of high-capacity adenoviral vectors, Gene Ther, 18, 1025, 10.1038/gt.2011.58 Candolfi, 2006, Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells, Mol Ther, 14, 371, 10.1016/j.ymthe.2006.05.006 Hsu, 2014, Development and applications of CRISPR-Cas9 for genome engineering, Cell, 157, 1262, 10.1016/j.cell.2014.05.010 Sternberg, 2015, Expanding the biologist's toolkit with CRISPR-Cas9, Mol Cell, 58, 568, 10.1016/j.molcel.2015.02.032 Khalil, 2016, The future of cancer treatment: immunomodulation, CARs and combination immunotherapy, Nat Rev Clin Oncol, 13, 273, 10.1038/nrclinonc.2016.25 Figueroa, 2015, Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy, Int Rev Immunol, 34, 154, 10.3109/08830185.2015.1018419